Fragment-based drug discovery has been recognized as a potential method to design novel molecules as this technique discovery utilizes comparatively small libraries of ‘fragments or ligands’ that are of low-molecular weights. Factors such as less time-consumption and easy access to biophysical fragment screening techniques are driving the growth of the global fragment-based drug discovery market. However, certain factors such as lower level of potency in few compounds derived from fragment screening and requirement of unique ‘fragment libraries’ for performing the studies might pull back the growth of fragment-based drug discovery market.
The drivers for the global fragment-based drug discovery market are its time-saving attributes and
The global fragment-based drug discovery market has been segmented into fragment screening and fragment optimization. The fragment screening segment is further sub-segmented into biophysical techniques and non-biophysical techniques. Biophysical techniques include isothermal titration calorimetry (ITC), nuclear magnetic resonance (NMR) spectroscopy, fluorescence polarization (FP), differential scanning fluorimetry (DSF), surface plasmon resonance, X-ray crystallography, assay (thermal shift), biolayer interferometry, capillary electrophoresis, mass spectrometry, and others (biochemical assays). The end-use applications encouraging the growth of this market are CROs, biopharmaceutical companies, and academic and research institutions. Geographically, the global fragment-based drug discovery market is divided into regions such as North America, Asia Pacific, Europe, Latin America, and Rest of the World.
North America dominated the global fragment-based drug discovery market due to growing awareness about this sector and the high level of its adoption by pharmaceutical companies. However, in the coming years, the Asia Pacific fragment-based drug discovery market will witness phenomenal growth due to the growing number of research and development activities.
